Table 1 Patient, cancer, and treatment characteristics, by duration of filgrastim prophylaxis

Patient

 Age (years), mean (SD)

54.1 (12.5)

57.4 (13.7)

59.2 (12.9)

 Men, %

23.5

23.1

21.7

 Chronic comorbidities, %

   Cardiovascular disease

1.6

2.0

1.9

   Diabetes

8.2

10.2

7.3

   Liver disease

1.0

0.9

0.5

   Renal disease

0.9

1.0

1.4

 History of other Conditions/ Events Prior to Chemotherapy Course, %

   Anemia

15.2

12.3

14.5

   Neutropenia

6.1

5.5

5.7

   Other blood disorders

2.2

2.0

2.4

   Infection

24.6

33.1

35.8

   History of hospitalization for any reason, %

50.6

49.3

49.7

   History of CINC-related hospitalization, %

6.6

9.1

10.4

   History of chemotherapy, %

9.0

6.4

6.9

   History of radiation therapy, %

6.5

4.3

4.0

 Pre-Chemotherapy Expenditures ($), Mean ± SD

34,736 (43,618)

33,913 (42,458)

34,480 (43,828)

 History of conditions/ events in prior cycles of same chemotherapy course, %

   Anemia

18.5

18.5

19.6

   Neutropenia

38.0

45.4

44.9

   Other blood disorders

1.5

1.5

2.2

   Infection

31.9

34.2

34.3

Cancer

 Type, %

   Female breast

48.2

49.6

49.6

   Non-Hodgkin’s Lymphoma

9.9

12.8

23.3

   Trachea, bronchus, lung

7.5

9.5

8.1

   Prostate

0.6

0.5

0.1

   Colon/Rectum

15.9

9.8

4.6

   Other

17.9

17.9

14.2

 Presence of metastases, %

   Bone

2.5

1.5

1.8

   Other Site

35.1

30.3

29.6

Chemotherapy

 Cycle number/ min. length of prior cycles in same chemotherapy course, %

  1

12.6

13.1

16.3

  2/12-19

5.9

4.3

4.8

  2/20-26

8.3

10.8

12.1

  2/27+

2.1

3.0

2.7

  > = 3/12-19

41.5

31.8

21.1

  > = 3/20-26

27.8

35.3

40.5

  > = 3/27+

1.7

1.8

2.5

 Number of Myelosuppressive Drugs, %

  1

24.3

20.0

14.5

  2

48.0

48.2

51.3

  3

20.6

25.4

31.3

  > = 4

7.1

6.4

3.0

 Receipt of Antimicrobial Prophylaxis, %

6.7

7.5

7.5

 Year of Chemotherapy, %

  2001-2003

19.2

19.0

26.9

  2004-2006

39.2

34.2

34.2

  2007-2010

41.7

46.8

38.9